Respiratorius AB (FRA:HF00) Other Stockholders Equity: €2.68 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HF00 Respiratorius AB FRA:HF00
34 GF Score
Price €0.27
View Full Analysis

What is Respiratorius AB Other Stockholders Equity?

Respiratorius AB FRA:HF00 34 Other Stockholders Equity is €2.68 Mil as of Mar. 2026. GuruFocus rates FRA:HF00 with a GF Score™ of 34/100.

Respiratorius AB's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €2.68 Mil.

Respiratorius AB's quarterly Other Stockholders Equity declined from Sep. 2025 (€1.26 Mil) to Dec. 2025 (€-1.36 Mil) but then increased from Dec. 2025 (€-1.36 Mil) to Mar. 2026 (€2.68 Mil).

Respiratorius AB's annual Other Stockholders Equity increased from Dec. 2023 (€-0.88 Mil) to Dec. 2024 (€-0.60 Mil) but then declined from Dec. 2024 (€-0.60 Mil) to Dec. 2025 (€-1.36 Mil).

Respiratorius AB Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Respiratorius AB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Respiratorius AB Other Stockholders Equity Chart

Respiratorius AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.33 -0.18 -0.88 -0.60 -1.36

Respiratorius AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Apr22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.34 1.26 -1.36 2.68
FRA:HF00
34GF Score
Respiratorius AB FRA:HF00
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Respiratorius AB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €2.68 Mil mean?
Respiratorius AB (FRA:HF00) has a Other Stockholders Equity of €2.68 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Respiratorius AB and its competitors.
Is Respiratorius AB's Other Stockholders Equity too high?
Respiratorius AB's current Other Stockholders Equity is €2.68 Mil. Overall, Respiratorius AB has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Respiratorius AB's Other Stockholders Equity compare to VRTX and REGN?
Respiratorius AB's Other Stockholders Equity of €2.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Respiratorius AB and its competitors. Respiratorius AB's current Other Stockholders Equity is €2.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Respiratorius AB stock overvalued right now?
Respiratorius AB (FRA:HF00) has a current Other Stockholders Equity of €2.68 Mil. The current Other Stockholders Equity is €2.68 Mil. Respiratorius AB's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Respiratorius AB (FRA:HF00), the current Other Stockholders Equity is €2.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Respiratorius AB Business Description

Other Exchanges RESP:Sweden
Address Scheelevagen 2, Medicon Village, Lund, SWE, 223 81
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
34GF Score

Get the complete analysis for FRA:HF00

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price